The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.
Defyrus Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our patented and award-winning Highlight® technology makes it easy to use disinfectants correctly.
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that identifies and advances promising science and pioneers efficient pathways for drug development for patients with severe rare diseases and cancer.
Linnaeus Therapeutics is a development stage biotech company engaged in the identification and development of small molecule agents for the treatment of cancer. Linnaeus is a Penn Center for Innovation UPstart company that was founded in 2016. Linnaeus is based upon discoveries from the Ridky lab at the University of Pennsylvania.